Bayer Acquires UK-Based Biotech KaNDy Therapeutics
Bayer, a leader in women’s health care, revealed that it would acquire KaNDy Therapeutics Ltd., a UK clinical-stage biotech company, to broaden its medicine development pipeline in the healthcare of women. Recently KaNDy Therapeutics Ltd. released the Phase IIb dose range finding results for its’ investigational substance, NT-814, neurokinin-1,3 receptor antagonist – a prospective first in class. Positive findings for the treatment of moderate to severe vasomotor symptoms were revealed in the outcomes of the study. Vasomotor symptoms (as night sweats, hot flashes, and flushes) are associated with menopause. In 2021, the beginning of the Phase III clinical trial is anticipated. The substance might generate peak sales potential of more than €1 billion worldwide.
Approximately 75% of women over the age of 50, going through menopausal change, experience symptoms of menopausal vasomotor. For those affected, these symptoms can be crippling for several years and may cause substantial incremental health care as well as financial costs.
Dr. Sebastian Guth, Bayer’s President of Pharmaceuticals, Americas Region, said, as a leader in Women’s Health, Bayer is aimed at supplying new options for females and their healthcare requirements. This procurement is another testament to our commitment to women’s health. This not only expands our pipeline but has the potential to provide a new treatment alternative.
Dr. Mary Kerr, Co-Founder, and CEO of KaNDy Therapeutics Ltd said, Bayer, has been our preferred companion because of its leading position in women’s healthcare. The company believes that this medicine under the possession of Bayer can be efficiently developed to become an important non-hormonal treatment option for vasomotor symptoms.
This procurement is one more vital milestone in enhancing Bayer’s portfolio of women’s healthcare. The expansion of Bayer’s partnership with Evotec was announced in 2020, to develop several clinical candidates for the therapy of polycystic ovary syndrome, with a new 5-year, multi-target collaboration. Bayer signed a special certificate contract with Daré Bioscience in January 2020, for the UNITED STATE market. It was concentrated on its investigational, hormone-free, monthly vaginal contraceptive currently in clinical development for preventing maternity.
This collaboration was facilitated by Bayer’s Licensing team and Pharmaceuticals Business Development.
The financial advisor to Bayer is Morgan Stanley, and the legal counsel of Bayer is Linklaters. The KaNDy Therapeutics Ltd’s financial advisor is Goldman Sachs International, and legal counsel is Goodwin.
Author: Sruthi S
